MedPath

TRULICITY

These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY. TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014

Approved
Approval ID

80d1e766-fefc-44b4-bec9-c7b0198ec08f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 3, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dulaglutide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-6456
Application NumberBLA125469
Product Classification
M
Marketing Category
C73585
G
Generic Name
Dulaglutide
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateJanuary 19, 2021
FDA Product Classification

INGREDIENTS (6)

Trisodium Citrate DihydrateInactive
Quantity: 1.37 mg in 0.5 mL
Code: B22547B95K
Classification: IACT
DULAGLUTIDEActive
Quantity: 1.5 mg in 0.5 mL
Code: WTT295HSY5
Classification: ACTIB
MannitolInactive
Quantity: 23.2 mg in 0.5 mL
Code: 3OWL53L36A
Classification: IACT
Anhydrous Citric AcidInactive
Quantity: 0.07 mg in 0.5 mL
Code: XF417D3PSL
Classification: IACT
Polysorbate 80Inactive
Quantity: 0.10 mg in 0.5 mL
Code: 6OZP39ZG8H
Classification: IACT
WaterInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.